Syndax Pharma 
Welcome,         Profile    Billing    Logout  
 3 Products   253 Diseases   3 Products   45 Trials   1655 News 


«12...10111213141516171819202122»
  • ||||||||||  resminostat (4SC-201) / 4SC, Yakult Honsha, entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma, BMS-345541 / BMS
    Journal:  Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling. (Pubmed Central) -  Dec 13, 2018   
    The observed induction of PD‑L1 was transcriptionally mediated by nuclear factor (NF)-κB, as shown by NF‑κB reporter assays, the nuclear accumulation of the p65 subunit of NF‑κB, inhibition by the IKK inhibitor, BMS‑345541, and histone the modification inhibitors, resminostat, entinostat or anacardic acid. Combined treatment with resveratrol and piceatannol also decreased tumor cell survival as indicated by the upregulation of the DNA damaging marker, γH2AX, the cleavage of caspase 3, the downregulation of the survival markers, p38-MAPK/c‑Myc, and G1-to-S cell cycle arrest.
  • ||||||||||  entinostat (SNDX-275) / Kyowa Hakko Kirin, Syndax Pharma
    Journal:  The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3. (Pubmed Central) -  Nov 30, 2018   
    NKG2D expression in NK cells is inhibited by the histone deacetylase (HDAC) inhibitor valproic acid (VPA) and enhanced by the narrow-spectrum HDAC inhibitor entinostat...NK cells from STAT3 wild-type mice downregulate NKG2D in response to VPA, but not NK cells from STAT3 knockout mice. These results show that VPA is a potent inhibitor of STAT3 phosphorylation and demonstrate that histone acetylation and STAT3 tyrosine705 phosphorylation cooperate in regulating NKG2D expression in NK cells.
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date, Metastases:  Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (clinicaltrials.gov) -  Sep 20, 2018   
    P2,  N=120, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Aug 2018 --> Aug 2022 | Trial primary completion date: Aug 2018 --> Aug 2022
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment open, Combination therapy:  Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma (clinicaltrials.gov) -  Sep 10, 2018   
    P2,  N=53, Recruiting, 
    Trial completion date: Aug 2018 --> Aug 2022 | Trial primary completion date: Aug 2018 --> Aug 2022 Not yet recruiting --> Recruiting
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Enrollment open, Metastases:  High Dose IL 2 and Entinostat in RCC (clinicaltrials.gov) -  Jul 16, 2018   
    P2,  N=46, Recruiting, 
    This trial suggests a promising clinical activity for entinostat in combination with high dose Il-2 in ccRCC patients, and provides the first example of an epigenetic agent being rationally combined with immunotherapy. Not yet recruiting --> Recruiting
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer (clinicaltrials.gov) -  Jul 10, 2018   
    P1b/2,  N=140, Active, not recruiting, 
    Not yet recruiting --> Recruiting Completed --> Active, not recruiting | Trial completion date: Apr 2018 --> Mar 2021 | Trial primary completion date: Apr 2018 --> Jul 2019
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Enrollment closed, Metastases:  Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer (clinicaltrials.gov) -  Jul 5, 2018   
    P2,  N=124, Active, not recruiting, 
    Completed --> Active, not recruiting | Trial completion date: Apr 2018 --> Mar 2021 | Trial primary completion date: Apr 2018 --> Jul 2019 Recruiting --> Active, not recruiting
  • ||||||||||  axatilimab (SNDX-6352) / Syndax Pharma, Incyte
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors (clinicaltrials.gov) -  Jun 27, 2018   
    P1,  N=48, Recruiting, 
    Trial primary completion date: May 2018 --> Apr 2022 N=24 --> 48 | Trial completion date: Jul 2018 --> Feb 2019 | Trial primary completion date: May 2018 --> Feb 2019
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  KEYNOTE-460: Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jun 26, 2018   
    P1,  N=30, Active, not recruiting, 
    N=24 --> 48 | Trial completion date: Jul 2018 --> Feb 2019 | Trial primary completion date: May 2018 --> Feb 2019 Recruiting --> Active, not recruiting | Trial completion date: Feb 2018 --> Feb 2019 | Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Jingzhuda (entinostat) / Syndax Pharma, EOC Pharma
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer (clinicaltrials.gov) -  Jun 21, 2018   
    P1,  N=40, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Feb 2018 --> Feb 2019 | Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2017 --> Dec 2018
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    New P2 trial, Metastases:  High Dose IL 2 and Entinostat in RCC (clinicaltrials.gov) -  Apr 17, 2018   
    P2,  N=46, Not yet recruiting, 
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Stivarga (regorafenib) / Bayer
    Enrollment open, Metastases:  To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer (clinicaltrials.gov) -  Mar 16, 2018   
    P1/2,  N=44, Recruiting, 
    OC phase results suggest that some women benefit from epigenetic therapy and/or reintroduction of endocrine therapy beyond progression but further study is needed. Not yet recruiting --> Recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  PEMDAC: Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye (clinicaltrials.gov) -  Mar 3, 2018   
    P2,  N=29, Recruiting, 
    Reversal of hypermethylation was seen in a subset of patients and correlated with improved PFS. Trial completion date: Jul 2023 --> Aug 2023 | Initiation date: Jan 2018 --> Feb 2018 | Trial primary completion date: Jul 2021 --> Aug 2021
  • ||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Trial primary completion date, Combination therapy, Epigenetic controller, Metastases:  Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) -  Feb 27, 2018   
    P1/2,  N=45, Active, not recruiting, 
    Trial completion date: Jul 2023 --> Aug 2023 | Initiation date: Jan 2018 --> Feb 2018 | Trial primary completion date: Jul 2021 --> Aug 2021 Trial primary completion date: Jun 2017 --> Feb 2019
  • ||||||||||  entinostat (SNDX-275) / Kyowa Hakko Kirin, Syndax Pharma
    Clinical, P3 data, Review, Journal:  E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. (Pubmed Central) -  Jan 23, 2018   
    These results prompted the development of E2112, a phase III registration trial which is investigating entinostat/placebo in combination with exemestane in patients with locally advanced or metastatic breast cancer who have experienced disease progression after a non-steroidal AI. E2112 aims to validate the preclinical and clinical findings supporting the role of HDAC inhibitors in overcoming resistance to endocrine therapy in breast cancer, and ultimately improve outcomes for patients with advanced breast cancer.